These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17385938)

  • 1. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?
    Motivala A; Pitt B
    Drugs; 2007; 67(5):647-55. PubMed ID: 17385938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone: a novel progestogen used as an oral contraceptive without an estrogen component.
    Paton DM
    Drugs Today (Barc); 2020 May; 56(5):321-328. PubMed ID: 32406879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women.
    Vitale C; Mammi C; Gambacciani M; Russo N; Spoletini I; Fini M; Volterrani M; Rosano GMC
    Int J Cardiol; 2017 Jan; 227():217-221. PubMed ID: 27843051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.
    Oelkers WK
    Steroids; 1996 Apr; 61(4):166-71. PubMed ID: 8732994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drospirenone, a new progestogen, for postmenopausal women with hypertension.
    Mallareddy M; Hanes V; White WB
    Drugs Aging; 2007; 24(6):453-66. PubMed ID: 17571911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.
    Ylikorkala O
    Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649
    [No Abstract]   [Full Text] [Related]  

  • 8. Drospirenone: a Latin American perspective for oestrogen-free oral contraception.
    Sales Vieira C; Celis C; Galán G; Hernández L; Díaz I; López J
    Eur J Contracept Reprod Health Care; 2021 Feb; 26(1):73-78. PubMed ID: 33155847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative cardiovascular effects of different progestins in menopause.
    Rosano GM; Fini M
    Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drospirenone- and levonorgestrel-containing oral contraceptives and the risk of gallbladder disease.
    Jick S; Pennap D
    Contraception; 2012 Sep; 86(3):220-3. PubMed ID: 22325114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
    Oelkers W
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):255-61. PubMed ID: 15134826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new hormone replacement therapy containing a progestogen with anti-mineralocorticoid activity.
    Stevenson JC
    J Br Menopause Soc; 2006 Mar; 12 Suppl 1():8-10. PubMed ID: 16513013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
    Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
    Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data.
    Whitehead M
    J Br Menopause Soc; 2006 Mar; 12 Suppl 1():4-7. PubMed ID: 16513012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
    Muhn P; Krattenmacher R; Beier S; Elger W; Schillinger E
    Contraception; 1995 Feb; 51(2):99-110. PubMed ID: 7750297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
    Svojanovská K
    Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.